Complement 3 Glomerulopathy (C3G)

Complement 3 Glomerulopathy (C3G) is a rare kidney disorder characterized by the abnormal deposition of complement component 3 (C3) in the glomeruli, the filtering units of the kidney. This condition is part of a broader category of diseases known as complement-mediated glomerulonephritis, which are driven by dysregulation of the complement system, a crucial part of the immune response.

Pathophysiology

The complement system is a group of proteins that play a significant role in immune defense, inflammation, and the clearance of pathogens. In C3G, there is an overactivation of the alternative complement pathway, leading to excessive deposition of C3 in the glomeruli. This deposition causes inflammation and damage to the kidney tissues, impairing their ability to filter blood effectively.

The dysregulation in C3G can be due to genetic mutations or acquired factors that affect the regulation of the complement pathway. These include mutations in complement regulatory proteins or the presence of autoantibodies that stabilize the C3 convertase enzyme, leading to its continuous activation.

Clinical Presentation

Patients with C3G may present with a variety of symptoms, which can range from mild to severe. Common clinical features include:

• Hematuria (blood in urine)
• Proteinuria (excess protein in urine)
• Hypertension (high blood pressure)
• Edema (swelling, particularly in the legs and around the eyes)
• Reduced kidney function, which can progress to chronic kidney disease or end-stage renal disease

The onset of symptoms can occur at any age, but C3G is often diagnosed in children and young adults.

Diagnosis

Diagnosing C3G involves a combination of clinical evaluation, laboratory tests, and kidney biopsy. Key diagnostic steps include:

1. Urinalysis: To detect hematuria and proteinuria.
2. Blood Tests: To assess kidney function and measure complement levels.
3. Kidney Biopsy: The definitive diagnosis of C3G is made through a kidney biopsy, which reveals the characteristic C3 deposits in the glomeruli. Immunofluorescence microscopy is used to visualize these deposits.

Treatment

There is currently no cure for C3G, and treatment focuses on managing symptoms and slowing disease progression. Treatment strategies may include:

• Blood Pressure Control: Using medications such as ACE inhibitors or angiotensin receptor blockers to manage hypertension and reduce proteinuria.
• Immunosuppressive Therapy: Corticosteroids and other immunosuppressive drugs may be used to reduce inflammation and immune activity.
• Complement Inhibitors: Emerging therapies targeting the complement pathway, such as eculizumab, are being investigated and may offer new treatment options.
• Supportive Care: Includes dietary modifications, such as reducing salt intake, and managing complications like edema.

Prognosis

The prognosis for individuals with C3G varies widely. Some patients may experience a slow progression of kidney disease, while others may rapidly progress to end-stage renal disease, requiring dialysis or kidney transplantation. Regular monitoring and early intervention are crucial in managing the disease and improving outcomes.

Research and Future Directions

Research into C3G is ongoing, with a focus on understanding the underlying mechanisms of complement dysregulation and developing targeted therapies. Advances in genetic testing and biomarker identification are improving diagnostic accuracy and enabling personalized treatment approaches.

Clinical trials are exploring the efficacy of novel complement inhibitors and other therapeutic agents, offering hope for more effective management of C3G in the future.